Washington University School of Medicine

Digital Commons@Becker

Open Access Publications

2015

An unusual cause of acute anemia in an immunosuppressed patient

Jamak Modaresi Esfeh
Cleveland Clinic

Whitney Jackson
Cleveland Clinic

Kianoush Ansari-Gilani
Washington University School of Medicine in St. Louis

Brian Putka
Cleveland Clinic

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation

Modaresi Esfeh, Jamak; Jackson, Whitney; Ansari-Gilani, Kianoush; and Putka, Brian, "An unusual cause of acute anemia in an immunosuppressed patient." *Gastroenterology Report*. 4, 3. 254 - 256. (2015).
https://digitalcommons.wustl.edu/open_access_pubs/8484

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

CASE REPORT

An unusual cause of acute anemia in an immunosuppressed patient

Jamak Modaresi Esfeh^{1,*}, Whitney Jackson¹, Kianoush Ansari-Gilani² and Brian Putka¹

¹Department of Gastroenterology & Hepatology, Cleveland Clinic, Cleveland, OH, USA and ²Department of Diagnostic Radiology, Washington University, St. Louis, MO, USA

*Corresponding author. Department of Gastroenterology & Hepatology, Cleveland Clinic Foundation, 9500 Euclid Avenue/A30, Cleveland, OH 44195, USA. Tel: +1-216-445-1901; Email: modarej@ccf.org

Abstract

Gastrointestinal mucormycosis is an uncommon, invasive, opportunistic fungal infection with a high mortality rate, seen more commonly in immunocompromised patients. This lethal infection has a wide range of presentations, from colonization of peptic ulcers to infiltrative disease and eventually vascular invasion. Here we present a case of upper gastrointestinal bleeding in an immunocompromised patient, which was proved to be secondary to gastric involvement by mucormycosis.

Key words: gastrointestinal bleeding; gastric mucormycosis

Introduction

Gastrointestinal mucormycosis is an uncommon and invasive, opportunistic fungal infection with a high mortality rate, seen more commonly in immunocompromised patients [1]. All portions of the gastrointestinal tract can become involved, with the stomach being the most common site [2]. This lethal infection has a wide range of presentations, from colonization of peptic ulcers to infiltrative disease and eventually vascular invasion. Here we present a case of upper gastrointestinal bleeding in an immunocompromised patient which was proved to be secondary to gastric involvement by mucormycosis.

Case presentation

A 65-year-old male with type 2 diabetes, interstitial lung disease and rheumatoid arthritis—the latter being treated with

chronic prednisone therapy and leflunomide—presented with periumbilical abdominal pain and dark, tarry stool for the previous 24 hours. Laboratory testing demonstrated a drop in hemoglobin from 13.0 to 6.7 g/dL.

A large mass was found on contrast-enhanced computed tomography (CT), extending from the esophago-gastric junction to the mid-gastric body and containing extensive infiltrative gas (Figure 1). Esophago-gastroduodenoscopy revealed a large, infiltrative mass with infiltration into the surrounding gastric mucosa, characterized by dusky, necrotic and ulcerative mucosa with multiple clots (Figure 2). Biopsies were taken and revealed broad, ribbon-like fungal elements infiltrating the gastric parenchyma, compatible with mucormycosis (Figure 3). Lactophenol cotton blue adhesive tape preparation from colony, showed sporangioophores directly over the sporangium, compatible with rhizopus (Figure 4).

The patient proceeded to surgery for sub-total gastrectomy with Roux-en-Y esophagojejunostomy.

Submitted: 19 December 2014; Revised: 31 December 2014; Accepted: 9 January 2015

© The Author(s) 2015. Published by Oxford University Press and the Digestive Science Publishing Co. Limited.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Figure 1. Post-contrast axial CT of the abdomen at the level of the gastric body reveals a large, loculated mass with a large amount of gas bubbles occupying most of the gastric body and fundus

Figure 2. Esophago-gastroduodenoscopy shows a large fungating mass starting at the esophago-gastric junction and extending inferiorly, with obscured landmarks and dusky, ulcerated and necrotic mucosa

Discussion

Gastrointestinal mucormycosis is an uncommon and invasive opportunistic fungal infection with a high mortality rate, seen more commonly in immunocompromised patients [1]. Some of the common risk factors for this infection include diabetes, inherited immunodeficiencies, immunosuppressants, solid organ- and hematopoietic stem cell transplant, malnutrition, and hematological malignancies, such as lymphoma and leukemia [2]. A meta-analysis of 929 cases revealed that the site of infection varies according to the underlying predisposing factor, with the paranasal sinuses being the most common site (39%, compared with 7% in the gastrointestinal tract) [3]. All portions of the gastrointestinal tract can become involved, with the stomach being the most common site [4].

Figure 3. A hematoxylin & eosin section from the stomach reveals suppurative inflammation with broad, ribbon-like fungal elements infiltrating the gastric parenchyma

Figure 4. Lactophenol cotton blue adhesive tape preparation from colony shows sporangioophores directly over the sporangium, consistent with *Rhizopus*

This lethal infection has a wide range of presentations, from colonization of peptic ulcers to infiltrative disease and eventually vascular invasion. Invasion of the vessels by this fungus causes thrombosis, infarction and tissue necrosis, which can present as gastrointestinal bleeding [1, 4]. The mortality rate from gastrointestinal mucor infection is up to 85%, which makes early diagnosis crucial [3]. Patients should be diagnosed based on their histological findings, since the culture is positive in only 30% of surgical specimens [5]. Treatment is a combination of early surgical debridement of infected tissue, along with systemic antifungal therapy (usually parenteral amphotericin B at 1 mg/kg/day or oral posaconazole at 400 mg, given twice daily) [1, 6, 7]. Early intervention with a combined approach will give the patient a better chance of survival, up to 70% [3].

Conflict of interest statement: none declared.

References

1. Mezhir JJ, Mullane KM, Zarling J et al. Successful non-operative management of gastrointestinal mucormycosis:

- novel therapy for invasive disease. *Surg Infect (Larchmt)* 2009; **10**:447–51.
2. Chhaya V, Gupta S and Arnaout A. Mucormycosis causing giant gastric ulcers. *Endoscopy* 2011; **43** Suppl 2 UCTN:E289–E290.
 3. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. *Clin Infect Dis* 2005; **41**:634–53.
 4. Thomson SR, Bade PG, Taams M et al. Gastrointestinal mucormycosis. *Br J Surg* 1991; **78**:952–4.
 5. Shetty S, Mambatta AK, Penmatsa KR et al. Ileal mucormycosis: a rare cause of lower gastrointestinal bleeding. *Ann Gastroenterol* 2014; **27**:169.
 6. Kalva N, Somaraju V and Puli S. A fatal case of gastrointestinal mucormycosis in immunosuppressed host. *Med J Armed Forces India* 2013; **69**:285–7.
 7. Dai Y, Walker JW, Halloush RA et al. Mucormycosis in two community hospitals and the role of infectious disease consultation: a case series. *Int J Gen Med* 2013; **6**:833–8.